EP
ARQT icon

Essential Partners’s Arcutis Biotherapeutics ARQT Stock Holding History

Essential Partners’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.39K Sell
358
-236
-40% -$5.5K ﹤0.01% 1240
2026
Q1 		$14K Hold
594
– – ﹤0.01% 1078
2025
Q4 		$17.3K Buy
594
+115
+24% +$2.94K 0.01% 969
2025
Q3 		$9.03K Buy
479
+92
+24% +$1.45K ﹤0.01% 1199
2025
Q2 		$5.43K Buy
+387
New +$5.42K ﹤0.01% 1025

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Essential Partners's ARQT Position: Q2 2026 in Review

Essential Partners reduced its Arcutis Biotherapeutics (ARQT) stake by 40% in Q2 2026, selling an estimated $5.5K and leaving 358 shares worth $9.39K. The position accounts for ﹤0.01% of the portfolio, ranked #1240.

Essential Partners first reported a position in ARQT in Q2 2025 and has held it in 5 quarters since. The position peaked at $17.3K in Q4 2025. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • Essential Partners held 358 shares of Arcutis Biotherapeutics worth $9.39K as of Q2 2026.
  • Essential Partners sold 236 Arcutis Biotherapeutics shares in Q2 2026, an estimated $5.5K.
  • Arcutis Biotherapeutics made up ﹤0.01% of Essential Partners's portfolio in Q2 2026, its #1240 holding.
  • Essential Partners first reported a position in Arcutis Biotherapeutics in Q2 2025 and has held it in 5 quarters since.
  • Essential Partners's Arcutis Biotherapeutics position peaked at $17.3K in Q4 2025.
  • 272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.